Navellier & Associates Inc. Makes New Investment in Guardant Health, Inc. $GH

Navellier & Associates Inc. acquired a new position in Guardant Health, Inc. (NASDAQ:GH) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 7,754 shares of the company’s stock, valued at approximately $484,000.

Several other institutional investors also recently modified their holdings of GH. Baillie Gifford & Co. lifted its position in Guardant Health by 6.6% in the third quarter. Baillie Gifford & Co. now owns 5,127,692 shares of the company’s stock worth $320,378,000 after purchasing an additional 317,906 shares during the period. Invesco Ltd. increased its holdings in Guardant Health by 27.3% in the 2nd quarter. Invesco Ltd. now owns 3,558,501 shares of the company’s stock valued at $185,184,000 after buying an additional 763,834 shares during the period. Geode Capital Management LLC raised its stake in shares of Guardant Health by 0.5% in the 2nd quarter. Geode Capital Management LLC now owns 2,920,714 shares of the company’s stock valued at $152,014,000 after buying an additional 13,088 shares in the last quarter. ARK Investment Management LLC lifted its holdings in shares of Guardant Health by 100.4% during the 2nd quarter. ARK Investment Management LLC now owns 2,823,497 shares of the company’s stock worth $146,935,000 after acquiring an additional 1,414,381 shares during the period. Finally, Franklin Resources Inc. boosted its position in shares of Guardant Health by 78.2% during the 2nd quarter. Franklin Resources Inc. now owns 2,319,947 shares of the company’s stock valued at $120,730,000 after acquiring an additional 1,018,144 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Guardant Health in a research note on Thursday, January 22nd. Wells Fargo & Company increased their target price on Guardant Health from $93.00 to $120.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Canaccord Genuity Group boosted their price target on Guardant Health from $100.00 to $125.00 and gave the company a “buy” rating in a research note on Monday, December 22nd. Leerink Partners upped their price target on Guardant Health from $115.00 to $155.00 and gave the company an “outperform” rating in a research report on Monday, December 15th. Finally, Citigroup lifted their price objective on Guardant Health from $100.00 to $135.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Twenty-one analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Guardant Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $106.86.

Guardant Health Stock Performance

Shares of GH opened at $107.58 on Thursday. The company has a market cap of $13.56 billion, a price-to-earnings ratio of -33.51 and a beta of 1.63. The stock has a fifty day moving average price of $106.44 and a two-hundred day moving average price of $83.20. Guardant Health, Inc. has a 52-week low of $34.88 and a 52-week high of $120.74.

Insider Buying and Selling at Guardant Health

In other Guardant Health news, CFO Michael Brian Bell sold 80,362 shares of the stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $103.14, for a total transaction of $8,288,536.68. Following the sale, the chief financial officer owned 28,052 shares of the company’s stock, valued at $2,893,283.28. This represents a 74.13% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Terilyn J. Monroe sold 55,167 shares of the firm’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $105.97, for a total transaction of $5,846,046.99. Following the completion of the sale, the insider owned 20,920 shares of the company’s stock, valued at $2,216,892.40. The trade was a 72.51% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 434,627 shares of company stock worth $45,592,052 over the last quarter. Corporate insiders own 6.10% of the company’s stock.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.